Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INCB059872 |
Synonyms | |
Therapy Description |
INCB059872 is a specific inhibitor of lysine specific demethylase 1 (KDM1A, LSD1) that increases tumor-suppressor gene expression through enhancing Histone H3 methylation, leading to anti-tumor effects (Cancer Res 2016;76(14 Suppl):Abstract nr 4704, PMID: 32422235). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCB059872 | KDM1A Inhibitor 15 | INCB059872 is a specific inhibitor of lysine specific demethylase 1 (KDM1A, LSD1) that increases tumor-suppressor gene expression through enhancing Histone H3 methylation, leading to anti-tumor effects (Cancer Res 2016;76(14 Suppl):Abstract nr 4704, PMID: 32422235). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02712905 | Phase Ib/II | INCB059872 | An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | Terminated | USA | NLD | BEL | 0 |
NCT03514407 | Phase I | INCB059872 | A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma | Terminated | USA | ITA | GBR | ESP | 0 |